Drug intelligence / Profile preview

STC2301

Development stage: Unknown
Lead developer: Staidson Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

STC2301 is a monoclonal antibody developed by Staidson Pharma (specifically Staidson Hongkong) that targets thymic stromal lymphopoietin (TSLP). TSLP is an epithelial-derived cytokine that plays a critical role in the initiation and persistence of type 2 inflammation, which is central to the pathogenesis of various allergic diseases. By neutralizing TSLP, STC2301 aims to modulate the inflammatory cascade upstream, potentially offering therapeutic benefits for patients with asthma and atopic dermatitis. As of early 2024, the drug is in Phase 1 clinical development.

Targets

TSLP (Thymic stromal lymphopoietin)

Beyond the preview

Go deeper on STC2301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STC2301.

Explore the full profile